Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Greg Malnassy

Showing results (1-10 of 8) with videos related to

Pageof 1
Sort By:
Frontiers in Oncology|April 1, 2021
The Epigenetic Regulation of Microenvironment in Hepatocellular CarcinomaFang Wang, Greg Malnassy, Wei Qiu
Gastroenterology|May 20, 2024
The Integrated Stress Response in Pancreatic Development, Tissue Homeostasis, and CancerGreg Malnassy, Leah Ziolkowski, Kay F Macleod, et al.
Hepatology Communications|March 3, 2022
Integrin subunit beta 8 contributes to lenvatinib resistance in HCCWei Hou, Bryan Bridgeman, Greg Malnassy, et al.
Cellular and Molecular Gastroenterology and Hepatology|March 13, 2025
Suppression of Hepatocellular Carcinoma by Deletion of SIRT2 in Hepatocytes via Elevated C/EBPβ/GADD45γFang Wang, Claudia Rose Keating, Yingchen Xu, et al.
Cellular and Molecular Gastroenterology and Hepatology|July 17, 2023
Inhibition of Abelson Tyrosine-Protein Kinase 2 Suppresses the Development of Alcohol-Associated Liver Disease by Decreasing PPARgamma ExpressionGreg Malnassy, Claudia R Keating, Shaimaa Gad, et al.
Haematologica|November 22, 2011
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909Hongtao Liu, Jeffrey L Johnson, Greg Koval, et al.
Blood|August 24, 2012
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaJerald P Radich, Kenneth J Kopecky, Frederick R Appelbaum, et al.
Blood|January 20, 2019
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403Wendy Stock, Selina M Luger, Anjali S Advani, et al.
Pageof 1

Showing results (1-10 of 8) with videos related to

Sort By:
Pageof 1
Frontiers in Oncology|April 1, 2021
The Epigenetic Regulation of Microenvironment in Hepatocellular CarcinomaFang Wang, Greg Malnassy, Wei Qiu
Gastroenterology|May 20, 2024
The Integrated Stress Response in Pancreatic Development, Tissue Homeostasis, and CancerGreg Malnassy, Leah Ziolkowski, Kay F Macleod, et al.
Hepatology Communications|March 3, 2022
Integrin subunit beta 8 contributes to lenvatinib resistance in HCCWei Hou, Bryan Bridgeman, Greg Malnassy, et al.
Cellular and Molecular Gastroenterology and Hepatology|March 13, 2025
Suppression of Hepatocellular Carcinoma by Deletion of SIRT2 in Hepatocytes via Elevated C/EBPβ/GADD45γFang Wang, Claudia Rose Keating, Yingchen Xu, et al.
Cellular and Molecular Gastroenterology and Hepatology|July 17, 2023
Inhibition of Abelson Tyrosine-Protein Kinase 2 Suppresses the Development of Alcohol-Associated Liver Disease by Decreasing PPARgamma ExpressionGreg Malnassy, Claudia R Keating, Shaimaa Gad, et al.
Haematologica|November 22, 2011
Detection of minimal residual disease following induction immunochemotherapy predicts progression free survival in mantle cell lymphoma: final results of CALGB 59909Hongtao Liu, Jeffrey L Johnson, Greg Koval, et al.
Blood|August 24, 2012
A randomized trial of dasatinib 100 mg versus imatinib 400 mg in newly diagnosed chronic-phase chronic myeloid leukemiaJerald P Radich, Kenneth J Kopecky, Frederick R Appelbaum, et al.
Blood|January 20, 2019
A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403Wendy Stock, Selina M Luger, Anjali S Advani, et al.
Pageof 1